SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (NASDAQ: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic liver ...

“Our presentations at AASLD this year demonstrate denifanstat’s impressive ability to address advanced fibrosis in MASH patients,” said David Happel, Chief Executive Officer of Sagimet. “A secondary ...

FAIRFIELD, N.J., May 10, 2023 /PRNewswire/ -- Winners from the American Liver Foundation's 2023 Liver Health Poster Competition were announced today. This competition showcases posters and a brief ...

Vanoglipel (DA-1241) is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism ...

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due ...

NEW YORK, May 9, 2025 /PRNewswire/ -- American Liver Foundation (ALF) is excited to announce today the 2025 winners of their Liver Health Poster Competition. This competition showcases posters and a ...